PubMed Health⌕ Search

Biomedical subjects

D Soutif

Publications and source records attributed to D Soutif.

8 recordsLinked to original sources
PubMed1992

Treatment of psoriatic arthropathy.

Psoriatic arthritis develops in 5% of patients with cutaneous psoriasis. Management is similar to that of other chronic inflammatory joint diseases, and the characteristic features of psoriatic arthritis should be considered: the disease is usually mild, with unpredictable flares and remissions, and skin disease is a concomitant feature. Nonsteroidal antiinflammatory agents are the mainstay of therapy and usually provide adequate control. Among long-term treatments, parenteral gold salts, methotrexate, and azathioprine have been shown to be effective. Retinoids are often used in patients with extensive skin lesions. Other treatments are currently being evaluated (auranofin, colchicine, D-penicillamine, sulfasalazine, cyclosporine, and gamma-interferon). Antimalarials are difficult to handle and may cause progression of skin lesions. Topical treatments are indicated in every case. Indications depend on the specific features of psoriatic arthritis, the clinical pattern, and the severity of the condition.

Anti-Inflammatory Agents, Non-Steroidal↗
PubMed1987

[Study of the plethysmographic amplification factor during vasodilator treatment. Healthy subject versus primary Raynaud phenomenon].

Digital arterial circulation before and after administration of a vasodilator orally was explored by mercury gauge pulsed plethysmography and photoplethysmography in 12 patients with primary Raynaud's phenomenon and results compared with those of 10 healthy volunteers. The amplification factor F, ratio of amplitude in reactive hyperemia over amplitude at rest was determined in the index before and after 8 mg daily of dihydroergokryptine over 4 weeks. Before treatment, for each of the two plethysmographic technics, a significant increase in mean factor F values was noted in the patients with Raynaud's phenomenon when compared with healthy controls. This is due to a decline in digital arterial flow at rest. Using the mercury gauge plethysmograph, a significant reduction in factor F was observed after vasodilator treatment corresponding to an increase in digital flow at rest without increase in flow during hyperemia. Using photoplethysmography, no significant variation in factor F was noted after treatment. Mercury gauge plethysmography, which measures global digital blood flow appears to be a more sensitive method than photoplethysmography, which measures dermal and hypodermal blood flow, for follow-up of effects of vasodilator treatment on Raynaud's phenomenon.

Adult↗
PubMedDate not supplied

[Hyperlipidemia and osteoarticular manifestations].

Hyperlipoproteinaemia, notably types II and IV, may give rise to various musculoskeletal disorders. Mono-, oligo- or polyarthritis, or even simple arthralgias, are often encountered in patients with severe type IIa hyperlipoproteinaemia, the most satisfactory tentative explanation for this being a microcrystalline pathology. Tendinitis is also frequent, particularly in children. The same manifestations have also been reported, although more occasionally, in type IV hyperlipoproteinaemia. Skeletal lesions, such as xanthoma or lipoma ossificans, are extremely rare. Other musculoskeletal disorders, including gout and aseptic osteonecrosis, are often associated with hyperlipidaemia. Some diseases may induce secondary hyperlipidaemia but have their own rheumatological manifestations. Finally, lipid-lowering drugs, such as fibrates and statines, sometimes induce disabling myalgias.

Bone Diseases↗